Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 7.10M | $5.0M | 3.17% | -1.38M | 2026-06-30 |
| Millennium Management LLC | 6.43M | $4.0M | 2.87% | +973.0K | 2026-06-30 |
| Citadel Advisors LLC | 4.79M | $3.0M | 2.14% | +412.6K | 2026-06-30 |
| Renaissance Technologies LLC | 4.28M | $3.0M | 1.91% | +567.3K | 2026-06-30 |
| BlackRock, Inc. | 4.01M | $2.0M | 1.79% | +304.8K | 2026-06-30 |
| Empery Asset Management, LP | 3.86M | $2.0M | 1.72% | -423.8K | 2026-06-30 |
| Marshall Wace, LLP | 3.50M | $2.0M | 1.56% | +797.8K | 2026-06-30 |
| Gsa Capital Partners LLP | 2.67M | $1.0M | 1.19% | +1.60M | 2026-06-30 |
| Burkehill Global Management, LP | 2.00M | $1.0M | 0.89% | -- | 2026-06-30 |
| Geode Capital Management, LLC | 1.83M | $1.0M | 0.82% | +274.7K | 2026-06-30 |
